PSTV
Plus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PSTV
Plus Therapeutics, Inc.
A U.S. pharmaceutical company that develops innovative, targeted radiotherapeutics for cancers
4200 Marathon Blvd., Suite 200, Austin, TX 78756
--
Plus Therapeutics, Inc. The company was incorporated as a California general partnership in July 1996 and was incorporated in Delaware in May 1997. Initially, it was known as MacroPore Biosurgery, and before that it was MacroPore. The Company is a US pharmaceutical company developing central nervous system (" CNS ") cancer-targeted radiotherapy drugs with advanced platform technology. The Company's novel radiopharmaceutical formulations and therapeutic drug candidates are designed to deliver safe and effective radiation doses to tumors. To achieve this, the company has developed innovative methods of drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres.
Company Financials
EPS
PSTV has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.04, meeting expectations. The chart below visualizes how PSTV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PSTV has released its 2025 Q3 earnings report, with revenue of 1.40M, reflecting a YoY change of -4.05%, and net profit of -4.42M, showing a YoY change of -53.90%. The Sankey diagram below clearly presents PSTV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
